Within the encompassing cohort of EGFR-mutated NSCLC cases examined, the treatment regimens involving osimertinib + CT and amivantamab + lazertinib emerged as particularly beneficial, showcasing notable enhancements in both PFS and OS. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.